Drug Approval | August 30, 2024
Natco Pharma announces submission of TABRECTA to USFDA
TABRECTA is the brand of Novartis. Natco believes it is the first company to have filed a substantially-complete ANDA
TABRECTA is the brand of Novartis. Natco believes it is the first company to have filed a substantially-complete ANDA
The company is making its mark through strategic initiatives, promising to become a significant presence in the evolving pharmaceutical sector
The low-profile, 2” Disc Top Lite closure offers lighter weight combined with premium customization options
Also received tentative approval for 137 mg
The partnership will provide health plans with an out-of-the-box compliance solution for CMS-9115 and CMS-0057 rules
The new bioeconomy policy rolled out by the Modi government is set to place India as a global leader in the years to come
Winrevair is the first activin signaling inhibitor therapy for PAH approved in Europe
The initiation of a second Phase 3 clinical trial for bomedemstat demonstrates company’s commitment to advancing research in myeloproliferative neoplasms (MPNs)
Honeywell Quality Management Review helps manufacturers boost efficiency and quality compliance
Nor UDCA is likely to be a first-in-class treatment option for NAFLD in India
Subscribe To Our Newsletter & Stay Updated
